Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Gets By With A Little Help From Its Hypertension Franchise

Executive Summary

Novartis is still counting on the strength of its pipeline and upcoming product launches to carry the firm through a period of slow growth despite the detrimental impact of the suspension of Zelnorm marketing and the entry of generic competition for Lotrel, the firm stressed during its July 17 second quarter earnings call

You may also be interested in...



The Heart Of A Pipeline: Can Novartis Keep The Cardio Portfolio Beating?

The challenge of a generation shift in cardiovascular drugs is not new for Novartis, but the upcoming phase-out of Diovan through 2012 looks more difficult. As the firm prepares to lose Diovan exclusivity, its pipeline reflects an attempt to reprise the time-honored big pharma strategy that carried it through the loss of Lotrel in 2007: mix major efforts to develop novel, first-in-class agents with a push to accelerate its already marketed brands

The Heart Of A Pipeline: Can Novartis Keep The Cardio Portfolio Beating?

The challenge of a generation shift in cardiovascular drugs is not new for Novartis, but the upcoming phase-out of Diovan through 2012 looks more difficult. As the firm prepares to lose Diovan exclusivity, its pipeline reflects an attempt to reprise the time-honored big pharma strategy that carried it through the loss of Lotrel in 2007: mix major efforts to develop novel, first-in-class agents with a push to accelerate its already marketed brands

Galvus Trial To Take Longer Than Predicted; Novartis Also Sees Tasigna Delay

Novartis is now facing a longer delay for its dipeptidyl peptidase-4 agent Galvus (vildagliptin) than previously predicted, since the safety study in patients with renal impairment requested by FDA will take at least six months, not "weeks" as originally suggested

Related Content

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel